Literature DB >> 19383269

Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment.

Michael A Lemp1, Kelly K Nichols.   

Abstract

ABSTRACT Like dry eye disease 15 years ago, blepharitis today is a poorly defined condition about which there is considerable misunderstanding. For a variety of reasons, there is little good data on either the prevalence of blepharitis or how eyecare practitioners currently treat it. The work reported herein consists of two recent studies: a telephone survey of a representative sample of the adult US population (n = 5,000) whose purpose was to discover the frequency of common ocular surface symptoms associated with blepharitis; and a study that queried a selected group of ophthalmologists (n = 120) and a similarly selected group of optometrists (n = 84) about the frequency of blepharitis in their practices, the existence comorbid conditions, and their management strategies. This data suggests that blepharitis symptoms are very common in the US population, with younger individuals reporting more, and more frequent, symptoms than older people, contrary to clinical dogma. Ophthalmologists and optometrists report that blepharitis is commonly seen in clinical practice in 37% and 47% of their patients, respectively, and it is widely agreed that meibomian gland dysfunction (MGD) is the most common cause of evaporative dry eye disease. In addition, management paradigms are shifting away from more traditional management with antibiotic ointment and warm compress therapy to prescription therapy for anterior and posterior blepharitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383269     DOI: 10.1016/s1542-0124(12)70620-1

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  61 in total

Review 1.  Interventions for chronic blepharitis.

Authors:  Kristina Lindsley; Sueko Matsumura; Elham Hatef; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  Meibocyte differentiation and renewal: Insights into novel mechanisms of meibomian gland dysfunction (MGD).

Authors:  Ho Sik Hwang; Geraint J Parfitt; Donald J Brown; James V Jester
Journal:  Exp Eye Res       Date:  2017-02-17       Impact factor: 3.467

Review 3.  The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee.

Authors:  Alan Tomlinson; Anthony J Bron; Donald R Korb; Shiro Amano; Jerry R Paugh; E Ian Pearce; Richard Yee; Norihiko Yokoi; Reiko Arita; Murat Dogru
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 4.  The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.

Authors:  Gerd Geerling; Joseph Tauber; Christophe Baudouin; Eiki Goto; Yukihiro Matsumoto; Terrence O'Brien; Maurizio Rolando; Kazuo Tsubota; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 5.  The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD.

Authors:  Debra A Schaumberg; Jason J Nichols; Eric B Papas; Louis Tong; Miki Uchino; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 6.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.

Authors:  Mark S Milner; Kenneth A Beckman; Jodi I Luchs; Quentin B Allen; Richard M Awdeh; John Berdahl; Thomas S Boland; Carlos Buznego; Joseph P Gira; Damien F Goldberg; David Goldman; Raj K Goyal; Mitchell A Jackson; James Katz; Terry Kim; Parag A Majmudar; Ranjan P Malhotra; Marguerite B McDonald; Rajesh K Rajpal; Tal Raviv; Sheri Rowen; Neda Shamie; Jonathan D Solomon; Karl Stonecipher; Shachar Tauber; William Trattler; Keith A Walter; George O Waring; Robert J Weinstock; William F Wiley; Elizabeth Yeu
Journal:  Curr Opin Ophthalmol       Date:  2017-01       Impact factor: 3.761

7.  Time course of changes in ocular wavefront aberration after administration of eye ointment.

Authors:  T Hiraoka; T Yamamoto; F Okamoto; T Oshika
Journal:  Eye (Lond)       Date:  2012-07-20       Impact factor: 3.775

8.  The combined effect of azithromycin and insulin-like growth factor-1 on cultured human meibomian gland epithelial cells.

Authors:  Yang Liu; Juan Ding
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-14       Impact factor: 4.799

9.  Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.

Authors:  Amalia Enríquez-de-Salamanca; Evangelina Castellanos; Michael E Stern; Itziar Fernández; Ester Carreño; Carmen García-Vázquez; Jose M Herreras; Margarita Calonge
Journal:  Mol Vis       Date:  2010-05-19       Impact factor: 2.367

10.  Azithromycin in DuraSite for the treatment of blepharitis.

Authors:  Jodi Luchs
Journal:  Clin Ophthalmol       Date:  2010-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.